Brent Warner - 01 Mar 2023 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: President, Gene Therapy
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2023
Net transactions value: -$142,401
Form type: 4
Filing time: 02 Mar 2023, 17:30:17 UTC
Previous filing: 01 Mar 2022
Next filing: 04 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+92,772	+30%	$0.000000	400,653	01 Mar 2023	Direct	F1
transaction	PSTX	Common Stock	Tax liability	$142,401	-26,617	-6.6%	$5.35	374,036	01 Mar 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Stock Option (Right to Buy)	Award	$0	+125,283		$0.000000	125,283	01 Mar 2023	Common Stock	125,283	$5.35	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2022.
F3	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.